JY BioMed is advancing a Natural Killer (NK) cell platform that utilizes the intrinsic ability of NK cells to recognize and eliminate tumor and virally infected cells without prior sensitization or MHC restriction. Unlike T cells, NK cells can respond to stressed or transformed cells through a balance of activating and inhibitory receptors, enabling rapid and antigen-independent immune responses. Our platform focuses on the expansion and activation of highly cytotoxic NK cells optimized for scale-up, cryopreservation, and integration into future therapeutic protocols. These efforts are designed to support applications across oncology and immunology, particularly in settings where adaptive immune responses may be insufficient or delayed.

​

Initial development programs include preclinical investigations in hematologic cancers, solid tumors, and immune dysregulation syndromes. All NK cell activities remain in the investigational stage, and are conducted in accordance with global regulatory and scientific standards for cell-based therapeutic research.

Regulatory Disclaimer

The gamma delta T cell therapy platform described is currently under preclinical development and has not been approved for clinical or commercial use.